Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
Conditions: Bladder Urothelial Carcinoma; Distal Urethral Carcinoma; Infiltrating Bladder Urothelial Carcinoma Associated With Urethral Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Proximal Urethral Carcinoma; Recurrent Bladder Carcinoma; Recurrent Prostate Carcinoma; Recurrent Urethra Carcinoma; Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter; Regional Urothelial Carcinoma of the Renal Pelvis and Ureter; Stage IV Bladder Cancer; Stage IV Prostate Cancer; Stage IV Urethral Cancer; Ureter CarcinomaInterventions: Drug: Gemcitabine Hydrochloride; Drug: Cisplatin; Other: Placebo; Biological: Bevacizumab; Other: Laboratory Biomarker AnalysisSponsor: National Cancer Institute (NCI)Active, not recruiting - verified November 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Avastin | Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Research | Ureter and Renal Pelvis Cancer | Urethral Cancer